Enduring Material

- https://www.youtube.com/watch?v=8_Gs9Rb1dwg

• The Colorado Medical Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Colorado Medical Society designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Cholestatic liver disease causes liver damage and fibrosis owing to bile stasis. It is represented by primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The pathogenesis of the disease is still unclear, although autoimmune mechanisms have been postulated and partially elucidated. Although the disease may progress slowly with only mild liver dysfunction, it may advance to liver cirrhosis or liver failure. People living with PBC are frequently symptomatic, experiencing a quality-of-life burden dominated by fatigue, itch, abdominal pain, and sicca complex.

As a medical treatment, ursodeoxycholic acid is widely used for PBC and has proved to be very effective against disease progression in cases of PBC. But new treatments are now available or in late-stage development, offering options in addition to Urso.

The seminar will explore the general natural history of PBC and PSC and provide information on the latest drug therapies currently available as well as those under investigation. A special section will focus on the frequent complaint of itching and will focus on the management of Cholestatic Pruritus.

CMS staff and planners of this activity have no relevant financial relationships with ACCME defined ineligible companies to disclose.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Paul J. Pockros, MD, Hepatology has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• ChemoMab Therapeutics - Contracted Research - Relationship Has Not Ended
• Intercept - Advisory Committee Member - Relationship Has Not Ended
• Gilead - Advisory Committee Member - Relationship Has Not Ended
• Ipsen - Advisory Committee Member - Relationship Has Not Ended
• Novo Nordisk - Ownership Interest - Relationship Has Not Ended
• UpToDate - Advisory Committee Member - Relationship Has Not Ended
• Gilead - Speakers Bureau - Relationship Has Not Ended
• Ipsen - Speakers Bureau - Relationship Has Not Ended
• Madrigal - Speakers Bureau - Relationship Has Not Ended

This activity is not commercially supported.

0 %

50 %

2/10/2025